Subscribe to our Newsletters !!
Few developments in science and technology have be
Even well‑validated LC–UV methods can produ
The recent rabies death of an 11 year old Canadian
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
Huntington's disease is one of rare and deadly genetic disorder characterized by uncontrolled movement, loss of intellectual ability and death.
The disease is generally transfer from parents to its offspring through mutation in Huntington Disease, This novel study recently released by scientists of American Academy of Neurology and details will be presented in American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Researcher develops a potential drug named “IONIS-HTTRx” that works as gene silencer and inhibits gene for producing Huntington protein in patients having disease. The great news is Scientists successfully tested this drug over mice and monkey and informed they all now start to test drug over human.
"It is very exciting to have the possibility of a treatment that could alter the course of this devastating disease," said clinical study principal investigator Blair R. Leavitt, MD, of the University of British Columbia in Vancouver.
"Right now we only have treatments that work on the symptoms of the disease." Leavitt notes the drug is still years away from being used in human clinical practice.
The drug is developed scientists at Ionis Pharmaceuticals in collaboration with their partners CHDI Foundation, Roche Pharmaceuticals and academic collaborators at University of California, San Diego. The preclinical studies led by Ionis Pharmaceuticals.
Note: The above story is for information purposes only for more information go through original story source.
Story source: American Academy of Neurology
